Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
July 5th, 2019
9.3K views
This article details the use of an anchored multiplex polymerase chain reaction-based library preparation kit followed by next-generation sequencing to assess for oncogenic gene fusions in clinical solid tumor samples. Both wet-bench and data analysis steps are described.
Overview
This article discusses a protocol for detecting gene fusions in clinical tumor samples using a multiplex PCR-based library preparation kit and next-generation sequencing. It highlights the importance of accurately distinguishing real fusions from artifacts in the analysis.
Key Study Components
Area of Science
- Oncology
- Genomics
- Clinical Diagnostics
Background
- Gene fusions can provide critical information for cancer diagnosis and treatment.
- The protocol allows for simultaneous assessment of multiple gene fusions.
- Understanding fusion partners is essential for accurate interpretation.
- Artifacts can complicate data analysis, making accurate identification challenging.
Purpose of Study
- To develop a reliable method for detecting oncogenic gene fusions.
- To improve diagnostic accuracy in clinical tumor samples.
- To facilitate better treatment decisions based on fusion status.
Methods Used
- Anchored multiplex polymerase chain reaction (PCR) for library preparation.
- Next-generation sequencing for comprehensive analysis.
- Simultaneous assessment of dozens of gene fusions.
- Data analysis to differentiate between real fusions and artifacts.
Main Results
- Successful detection of multiple gene fusions in tumor samples.
- Identification of critical fusions that inform clinical decisions.
- Challenges in distinguishing true fusions from artifacts were noted.
- The method demonstrated potential for improving patient outcomes.
Conclusions
- The protocol is effective for detecting oncogenic gene fusions.
- Accurate analysis is crucial for clinical applications.
- Further refinement of data analysis methods is needed to reduce artifacts.
Frequently Asked Questions
What are gene fusions?
Gene fusions occur when two genes become joined together, which can lead to cancer development.
How does this method improve cancer diagnosis?
It allows for the simultaneous detection of multiple gene fusions, providing comprehensive information for diagnosis.
What are the challenges in analyzing gene fusions?
Distinguishing between true fusions and artifacts is a significant challenge in data analysis.
Why is it important to detect gene fusions?
Detecting gene fusions can inform treatment decisions and improve patient outcomes in cancer therapy.
What technology is used in this study?
The study utilizes anchored multiplex PCR and next-generation sequencing for gene fusion detection.
Can this method be used for all types of tumors?
The method is designed for clinical solid tumor samples, but its applicability may vary by tumor type.
Executive Industry Relevance
Accurate detection of oncogenic gene fusions is pivotal for translational oncology pipelines, directly impacting diagnostic, prognostic, and therapeutic decision points. Anchored multiplex PCR followed by next-generation sequencing (NGS) enables simultaneous assessment of dozens of fusion events, supporting high-confidence target validation and portfolio triage. This approach addresses the growing demand for multiplexed, artifact-resistant fusion detection in clinical and preclinical R&D.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables comprehensive interrogation of fusion-driven oncogenic pathways for mechanistic de-risking.
- Supports functional target validation by confirming fusion presence independent of partner identity.
- Facilitates predictive confidence in candidate selection for downstream translational studies.
Screening & Assay Development
- Prepares validated nucleic acid libraries for high-throughput fusion screening workflows.
- Delivers standardized, reproducible, and quantitative fusion detection outputs for assay development.
- Enables scalable multiplexing, supporting efficient evaluation of multiple targets in parallel.
Translational & Preclinical Research
- Aligns fusion detection with disease-relevant biomarkers for translational continuity.
- Provides robust evidence for risk-adjusted advancement of fusion-driven therapeutic programs.
- Reduces biological ambiguity in preclinical model selection and validation.
Pipeline & Workflow Integration
This anchored multiplex PCR-NGS workflow integrates from early discovery through translational research, bridging target validation, assay development, and preclinical biomarker alignment.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling unbiased fusion partner detection.
- Screening: Provides reproducible, quantitative fusion readouts for reliable assay standardization.
- Analytics: Generates detailed read statistics and visualization outputs to distinguish true fusions from artifacts.
- Translational Research: Ensures continuity of fusion biomarker detection from discovery to preclinical validation.
- Enterprise Reuse: Offers a reusable, scalable platform for ongoing fusion analysis across diverse oncology programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in fusion-driven oncology research.
- Operational Value: Standardizes multiplexed fusion detection with high reproducibility and scalability.
- Strategic Value: Improves go/no-go decisions and capital efficiency by minimizing false positives and artifacts.
- Portfolio Impact: Enables risk-adjusted prioritization of fusion-targeted assets and programs.
Implementation Considerations
- Requires expertise in molecular biology, NGS library preparation, and bioinformatics analysis.
- Demands access to thermocyclers, qPCR instruments, and NGS platforms.
- Necessitates rigorous cross-team standardization for artifact discrimination and data interpretation.
- Adaptable to various solid tumor sample types, but RNA quality and fixation methods may affect results.
- Manual review of fusion calls is critical to ensure accuracy and minimize false positives.
Biopharma FAQs
Why does null hypothesis testing matter for fusion call validation?
Null hypothesis testing is essential to distinguish true gene fusions from artifacts, ensuring that only statistically significant fusion events inform target validation and downstream decisions.
How does independent variable isolation fit anchored multiplex PCR workflows?
Isolating variables such as RNA input quality and primer specificity is critical in anchored multiplex PCR to attribute detected fusions to biological events rather than technical artifacts, supporting reliable discovery outputs.
What do quantitative dependent variable measurements enable in NGS fusion analysis?
Quantitative metrics like supporting read counts, unique start sites, and alignment quality enable objective assessment of fusion calls, facilitating robust comparison across samples and conditions.
Why are replication requirements important for cross-functional fusion analysis?
Replication ensures that detected fusions are reproducible across technical and biological replicates, supporting cross-functional confidence in assay results and collaborative decision-making.
What statistical analysis capabilities are required before implementing fusion detection in R&D?
Robust statistical tools are needed to filter artifacts, assess read alignment, and validate fusion calls, ensuring that only high-confidence events advance in the R&D pipeline.
Chapters in this video
0:04
Title
0:49
Random Priming and First Strand cDNA Synthesis
1:55
Ligation Step 2 and Bead Purification
4:25
First PCR and Bead Purification
5:48
Library Quantitation and Sequencing
7:41
Assay Data Interpretation
8:39
Results: Sample Summary and Fusion Calls
9:27
Conclusion
